PT  - JOURNAL ARTICLE
AU  - Ghafari, Mahan
AU  - Karlinsky, Ariel
AU  - Watson, Oliver J
AU  - Ferretti, Luca
AU  - Katzourakis, Aris
TI  - Detailed reconstruction of the Iranian COVID-19 epidemic reveals high attack rates of SARS-CoV-2 in several provinces
AID  - 10.1101/2021.10.04.21264540
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.04.21264540
4099  - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264540.short
4100  - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264540.full
AB  - Since the first cases of COVID-19 were reported in Qom, Iran, almost 19 months ago, the transmission dynamics across the country and the health burden of COVID-19 has remained largely unknown due to the scarcity of epidemiological analyses and lack of provincial data on the number of COVID-19 cases and deaths. For the first time, we reconstruct the epidemic trajectory across the country and assess the level of under-reporting in infections and deaths using province-level age-stratified weekly all-cause mortality data. Our estimates suggest that as of 2021-09-17, only 48% (95% confidence interval 43-55%) of COVID-19 deaths in Iran have been reported. We find that in the most affected provinces such as Qazvin, Qom, and East Azerbaijan approximately 0.4% of the population have died of COVID-19 so far. We also find significant heterogeneity in the estimated attack rates across the country with 11 provinces reaching close to or higher than 100% attack rates. Despite a relatively young age structure in Iran, our analysis reveals that the infection fatality rate gradually increased over time in several provinces and reached levels that are comparable some of the high-income countries with a larger percentage of older adults, suggesting that limited access to medical services, coupled with undercounting of COVID-19-related deaths, can have a significant impact on COVID-19 fatalities. These results also show that despite several waves of infection and high attack rates in many provinces with largely unmitigated epidemics, herd immunity through natural infection has not been achieved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMG is funded by the Biotechnology and Biological Science Research Council (BBSRC), grant number BB/M011224/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work does not include any clinical trial or prospective interventional study data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used for the analysis are available online on our GitHub repository (github.com/mg878/Iran_WeeklyMortality). For regular updates on excess mortality in Iran, you can visit: https://github.com/akarlinsky/world_mortality. https://github.com/mg878/Iran_WeeklyMortality